2023 Industry Symposium: Friday

Friday, June 16TH, 2023 – 8:00-9:00 AM
Clinical Considerations in the Management of BRCA-mutated Early Breast Cancer – A Multidisciplinary Perspective

Room: Vanity Ballroom (Plenary Room)

Multidisciplinary Panel

Jan-Willem Henning MBChB FRCPC (Moderator)
Medical Oncologist, Tom Baker Cancer Centre
Clinical Associate Professor, University of Calgary
Calgary, Alberta

Nathalie Bolduc MSc CCGC CGC
Genetic Counsellor
Project Manager – Operations, McPeak-Sirois
Montreal, Quebec

Saima Hassan MD PhD FRCSC
Surgical Oncologist, Assistant Professor
Scotiabank Chair in the Diagnosis and Treatment of Breast Cancer
Centre Hospitalier de l’Université de Montréal
Montreal, Quebec

Patient Perspective

Ms. Ana Rice
Calgary, Alberta


Over the past few decades, the presence of a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant has prompted surveillance measures and prevention strategies. More recently, clinical trials have shown the benefits of PARP inhibitor therapies in BRCA-mutated solid tumours including germline BRCA-mutated (gBRCAm), HER2 negative high-risk early breast cancer.

The transition of new treatment strategies from the clinical trial setting to routine practice can be challenging. “Practice changing” trial results can indeed require new thinking, new approaches, and new collaborations in day-to-day practice.

Adopting PARP inhibitor therapy as a treatment option in early HER2 negative breast cancer requires the integration of timely hereditary cancer genetic testing into the breast cancer care pathway following diagnosis. However, the growing demand for genetic testing across tumour sites is increasing the strain on medical genetics services.

This session brings together a multidisciplinary panel from different institutions to explore the challenges of obtaining timely germline BRCA testing in their practice settings. The panelists aim to identify common unmet needs and potential solutions to the challenges of facilitating hereditary cancer testing and obtaining results for early breast cancer treatment decisions.

Learning Objectives:

At the completion of the program, participants should be able to:

  • Identify patients with early breast cancer who should undergo germline BRCA testing.
  • Communicate with multidisciplinary team members regarding roles and responsibilities in facilitating timely hereditary cancer genetic testing.
  • Integrate PARP inhibitor therapy considerations into treatment planning for patients with gBRCAm early triple-negative breast cancer and gBRCAm HR positive/HER2 negative early breast cancer.

Friday, June 16th, 2023 – 12:45-13:45
The Present and Future of Breast Cancer Treatment and Management
What we know for sure for mBC, what we can expect for eBC

Room: Vanity Ballroom (Plenary Room)


Karen A Gelmon MD, FRCPC
Professor of Medicine, University of British Columbia
Medical Oncologist, BC Cancer
Chair, UBC/BC Cancer Research Ethics Board
Fellow, Canadian Academy of Health Sciences


Katarzyna Jerzak MD, MSc, FRCPC
Medical Oncologist, Sunnybrook Odette Cancer Centre
Associate Scientist, Sunnybrook Research Institute
Assistant Professor, Department of Medicine, University of Toronto

Sara Soldera MD, FRCPC
Medical Oncologist, Integrated Cancer Centre of Montérégie
Assistant Professor, Faculty of Medicine and Health Sciences, Department of Medicine, Sherbrooke University
Medical Director of clinical research for hematology and oncology, Centre de recherche Charles-Le Moyne (CRCLM)


Given the rapidly evolving science, and maturation of clinical trial data in HR+ HER2- breast cancer, the ability to remain up to date can be challenging. Our distinguished faculty have put together a presentation that will review the evolving clinical science and impact on the treatment and management of metastatic breast cancer. The faculty will also address how this will shape the future of early breast cancer.

This faculty exchange aims to initiate discussion and recommendations towards improving breast cancer patient quality of life and outcomes.

Learning Objectives:

  • Review clinical implications of recent data on metastatic breast cancer
  • Describe the clinical impact on treatment, management and outcomes for patients with metastatic breast cancer
  • Upcoming implications for other early breast cancer